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Abstract
Liquid biopsy solutions are available for niche clinical applications. The patient 
benefits of such solutions are evident: ease of sampling, acceptable and repeatable. 
To date a number of solutions have received regulatory approval with more compre-
hensive, multi-cancer companion diagnostic approaches receiving approval in late 
2020. Given these breakthrough advances and the ongoing clinical studies in early 
detection of cancer, the liquid biopsy field is making strides in technology. While 
circulating tumour DNA (ctDNA) solutions are quickly penetrating the market, 
strides in circulating tumour cells (CTC) and extracellular vesicles (EV) technolo-
gies is unlocking their potential for liquid biopsy. ctDNA solutions are paving the 
way towards clinical translation into the distinct applications across the cancer 
continuum. This chapter presents a detailed review of current approved liquid 
biopsy tests and provides a summary of advanced-stage prospective technologies 
within the context of distinctive clinical applications.
Keywords: circulating tumour cells, CTC, extracellular vesicles, EV, cfDNA, ctDNA, 
methylation, liquid biopsy, cancer screening, precision medicine, companion 
diagnostics
1. Introduction
Precision medicine is driven by discoveries in cancer biology that enable  
targeted therapy against specific oncogenic molecular targets. Using small selective 
inhibitory molecules or monoclonal antibodies, therapies aim to effectively target 
tumour cells with minor effects on normal cells [1]. Targeted therapies significantly 
contribute to improved cancer survival, however the results have not been com-
mensurate with expectations [2]. Tumours accumulate mutations, many of which 
are passenger or dispensable aberrations that can be bypassed to confer resistance. 
Malignant cells interact and exploit their immediate and distant microenvironment. 
Tumours exhibit clonal evolution that results in heterogeneity [3, 4]. Cancer is a 
cell disorder characterised not only by its genetics but transcriptomic, proteomic 
expression patterns and cellular interactions. This is driving an integrative approach 
to cancer diagnosis and therapeutic options [5–7].
Until recently, precision medicine was limited to the solid tissue space but is 
now becoming established in the liquid biopsy field with several approved solu-
tions (Tables 1 and 2). The broad term, liquid biopsy, alludes to a test or series of 
tests that can provide information comparable and potentially beyond the limits of 
the tissue biopsy harnessing body fluid constituents. Body fluids investigated for 







Test (Manufacturer) Technology Biomarker Cancer Type Approval Application Sample
CellSearch® (Menarini Silocon 
Biosystems)
CTC immuno-isolation 
and detection by 
immune-fluorescence
CTC with CD45-, EpCAM+ 






Cobas® EGFR mutation test V2 
(Roche)
PCR EGFR NSCLC FDA CDx Plasma
Therascreen (Qiagen) PCR • PIK3CA • Breast FDA / 
CE-IVD
CDx Blood
• KRAS • CRC
• BRAF • CRC
• EGFR • NSCLC
• FGFR • Urothelial
Target Selector™ (Biocept) [8] Switch-Blocker, qPCR, NGS EGFR NSCLC CE-IVD CDx Blood / 
FFPE
OncoBEAM (Sysmex) Digital PCR KRAS & NRAS mCRC CE-IVD CDx Plasma
Idylla (Biocartis) PCR • KRAS • mCRC CE-IVD CDx Plasma
• NRAS, BRAF • mCRC
HCCBlood Test (Epigenomics AG) [9] Bisulfite converted DNA & 
PCR
SEPT9 methylation HCC (patients with 
liver cirrhosis)
CE-IVD Diagnostic aid Plasma
Epi proColon® (Epigenomics AG) 
[10, 11]
Bisulfite converted DNA & 
PCR
SEPT9 methylation CRC FDA / 
CE-IVD
Ancillary Screening Plasma
COLOGUARD (ExactSciences) [12] QuARTS & Immunoassay BMP3 & NDRG4 
methylation, KRAS, ACTB 
Haemoglobin
CRC or advanced 
adenoma
FDA Ancillary screening Stool
IntPlex® (DiaDx) [13, 14] PCR • BRAF • mCRC CE-IVD CDx Plasma












Xpert® Bladder Cancer Detection 
Xpert® Bladder Cancer Monitor 
(Cepheid) [15]




















PCR FGFR3 and TERT PCR NMIBC (patients 
with haematuria)







restriction Enzyme digestion, 
PCR
15 DNA methylation markers Bladder CE-IVD Surveillance for 
recurrence
Urine
Table provides a general overview and may not be exhaustive [CDx: Companion diagnostic; mCRC: metastatic colorectal carcinoma; CTC: Circulating tumour cells; ddPCR: droplet digital Polymerase 
chain reaction; FDA: Food & Drug Administration; FISH: Fluorescent in situ hybridisation; HCC: Hepatocellular carcinoma; CE-IVD: In vitro Diagnostic device certification; NMIBC: Non-muscle invasive 
bladder cancer; NSCLC: Non-small cell lung carcinoma; PCR: Polymerase chain reaction; QuARTS: Quantitative allele-specific real-time target and signal amplification; RT-PCR: reverse transcription 
PCR] [18, 19].
Table 1. 






Pan-Cancer / Multi-cancer Indication
Test (Manufacturer) Technology Biomarker Cancer Type Approval Application Sample
FoundationOne Liquid CDx (FoundationOne) [20] NGS
(324 genes)
• ALK, EGFR • NSCLC FDA CDx Plasma
• BRCA1/2 • Ovarian
• BRCA1/2 & ATM • Prostate
• PIK3CA • Breast
Guardant360 (Guardant Health) [21, 22] NGS
(73 genes)
• Tumour mutation profiling • Any solid tumour FDA CDx Plasma
• EGFR • NSCLC
Table provides a general overview and may not be exhaustive. [CDx: Companion diagnostic; mCRC: metastatic colorectal carcinoma; FDA: Food & Drug Administration; NGS: Next-generation sequencing; 
NSCLC: Non-small cell lung carcinoma] [18, 19].
Table 2. 
Overview of current approved (FDA/IVD) ctDNA liquid biopsy solutions indicated for use with 2 or more solid cancers.
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urine [16], cerebrospinal fluid [23], stool [24], breast milk [25], saliva/sputum, 
oesophageal brushing, Pap smears/brushing [26], tears [27], pleural effusion [28] 
and ascitic fluid [29].
Liquid biopsy testing may encompass investigations of circulating tumour DNA 
(ctDNA) or cell-free DNA (cfDNA) and RNA (ctRNA), circulating tumour cells 
(CTCs), tumour-derived extracellular vesicles (EVs) and tumour-educated platelets 
[30]. Rapidly advancing technologies for immunoprofiling of leukocytes and T-cell 
receptor (TCR) profiling also present a potential liquid biopsy tool with a particular 
role in metastatic cancer patients for immunotherapy [31, 32].
The potential applications of liquid biopsy are numerous and throughout the 
cancer journey:
1. Cancer detection for screening or earlier detection [33, 34],
2. Diagnosis / Prognosis/Predictive (Companion Diagnostics, CDx) [30],
3. Therapeutic response monitoring (Detection of resistance mechanisms) [35, 36],
Figure 1. 
Comparison of workflows of emerging liquid biopsy tools with routine cancer diagnostics by tissue biopsy. 
Liquid biopsy solutions remain complimentary to the clinical standard of care. [CTC: Circulating tumour cells; 
EVs: Extracellular vesicles; ctDNA: Circulating tumour DNA; FISH: Fluorescent in situ hybridisation; H&E: 
Haematoxylin and eosin; IHC: Immunohistochemistry; TAT: Turn-around time; created with BioRender.com].
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4. Minimal Residual Disease detection [37],
5. Post-remission surveillance to predict/detect relapse, metastases and clonal 
evolution [37, 38].
The main advantages of a liquid biopsy assay relate to the ease of sampling. 
Collecting the sample is generally not invasive and repeatable enabling longitudinal 
monitoring. The risk of complications and pain from sample collection is minimal 
presenting a very acceptable procedure that beckons better uptake as a screening 
procedure. Liquid biopsy methods are less laborious than tissue biopsy methods and 
can be analysed in a much shorter time-frame (Figure 1). Moreover, liquid biopsies 
offer an overall snapshot of the tumour which represents distinct tumour clones, 
mitigating tumour region selection bias [30]. Monitoring cancer over time also pro-
vides insight on the temporal heterogeneity, a potential tool to study mechanisms of 
response and resistance [32, 39].
Following is a review of the advances of liquid biopsy in the context of the  
current state of tissue molecular pathology for clinical application. A brief illustra-
tion of future prospects is also described based on ongoing clinical studies.
2.  Molecular pathology: overcoming challenges for solid and liquid 
biopsy
Challenges to comprehensively characterise cancer in the clinical setting exist, 
relating to pre-analytical (sample collection & processing), analytical and post-
analytical factors. Molecular pathology of solid cancer on formalin-fixed paraffin 
embedded (FFPE) tissue presents technical challenges arising from tissue fixation 
and processing but also sample availability.
A study evaluating factors for next-generation sequencing (NGS) testing 
failure showed that on average 22.5% of cases do not meet quality requirements. 
Insufficient tissue or insufficient DNA accounted for 62% and 29% of failures 
with 6% failing at library preparation [40]. The study highlights increased fail-
ure from fine needle aspirates and biopsy specimens with a low failure rate in 
excisional specimens (1.7%) [41]. Whole genome sequencing approaches show 
non-uniform coverage in FFPE DNA samples resulting in sub-optimal somatic 
copy number alteration detection. Nonetheless clinically actionable variants are 
generally detected [42]. Sensitive NGS applications require good quality DNA to 
achieve adequate assay performance and coverage. Recent developments in DNA 
extraction methods and optimisation improve assay performance [42, 43]. In fact 
NGS solutions have been achieving regulatory approval such like Oncomine Dx 
(ThermoFisher Scientific) for targeted therapies in non-small cell lung carcinoma 
(NSCLC) [44]; Praxis (Illumina) characterising 56 KRAS/NRAS mutations for 
colorectal cancer companion diagnostics (CDx); Memorial Sloan Kettering-
Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), the 
first U.S. Food & Drug Administration (FDA) approved tissue profiling test that 
detecting aberrations across 341 cancer genes for solid cancer tissue diagnostics but 
not prescriptive for any specific therapeutic product [45]; and FoundationOne CDx 
which is the first FDA-approved broad CDx test that is clinically and analytically 
validated for all solid tumours for therapeutic indication and has a success rate of 
>95% on FFPE [46].
Targeted gene panels or single gene polymerase chain reaction (PCR) assays 
are more easily translated to clinical application given their very specific intended 
use. Recent advances can mitigate the effects of DNA fragmentation and PCR 
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inhibition [47]. Technical challenges are greater for detection of RNA signatures 
due to high degree of RNA fragmentation and introduced technical bias [48]. A 
study assessing the performance of PCR on RNA derived from FFPE reports that 
only 50% (37/74) of samples were informative. RNA profiling on FFPE samples 
requires alternative technologies that can robustly detect degraded RNA with 
reduced technical bias [49–51].
Liquid biopsy options involve far less sample processing and better sample qual-
ity. Nonetheless tumour signatures are generally rare, similar to finding ‘the needle 
in a haystack’, and assays require high sensitivity to avoid false negative results. In 
the search for a sensitive, specific and reliable method, liquid biopsy technologies 
are becoming more diverse and complex [52–54]. Moreover, pre-analytical consid-
erations are critical to ensure high sensitivity and reproducible performance. These 
requirements vary depending on the analysed liquid biopsy component. Expert 
recommendations for minimal requirements for clinical cfDNA testing have been 
published to emphasise the need for standardisation of the test processes [55].
3. Current state of liquid biopsy application
3.1 Liquid biopsy for companion diagnostics
A particular study of previously untreated metastatic non-small cell lung 
carcinoma (NSCLC) shows that cfDNA technologies have the potential to detect 
guideline-recommended biomarkers with a higher sensitivity compared to standard 
of care tissue genotyping methodology [22]. Currently, ctDNA assays are being rec-
ommended for use in lung patients with progression of secondary clinical resistance 
and in some clinical settings where tissue is limited or insufficient for molecular 
testing. ctDNA assays are not recommended for the diagnosis of primary lung 
tumours [56]. ctDNA liquid biopsy solutions are currently approved as additional 
tools to the standard of care and when results are negative, tissue testing is recom-
mended when available. Lung cancer tissue is not easily available and sampling 
implies potential serious complications such as pneumothorax, haemorrhage and 
respiratory failure. Only 50% of cases in the MarkER Identification Trial (MERIT) 
trial had sufficient sample for the planned molecular analyses [40]. This presents a 
clinical need for liquid biopsy to potentially identify a route for targeted treatment.
Advanced-stage technologies within the liquid biopsy field harness ctDNA. 
These approaches mainly focus on hallmark mutations or other changes in the DNA 
(methylation). The first FDA approved ctDNA liquid biopsy was the cobas® EGFR 
mutation test V2 (Roche) as a companion diagnostic [57]. This was followed by 
several other targeted panel companion diagnostics (Table 1). The main available 
plasma liquid biopsy solutions detect mutations in clinically actionable biomarkers 
that predict response to specific targeted therapies. The main biomarkers detected 
are EGFR, FGFR, KRAS, NRAS, BRAF and PIK3CA.
Selected diagnostic panels are useful as companion diagnostics for clinical trials 
and patient selection for specific targeted therapeutics. Nonetheless, established 
targets would then be integrated into larger diagnostic panels that provide a 
comprehensive and exhaustive approach to cancer diagnostics. Recently the FDA 
approved the first two NGS-based liquid biopsy solutions: Guardant360 (August, 
2020) and FoundationOne CDx (November 2020) (Table 2). Unlike PCR-based tar-
geted panels, large NGS panel tests interrogate a large-set of genes generating more 
clinically useful information but present a challenge to validate and regulate [58]. 
Similar to tissue-based NGS approaches, generated clinical information assists the 
definition of a spectrum of potential therapeutic options to identify a sequence of 
Histopathology and Liquid Biopsy
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treatments to achieve optimised response [59]. In contrast, to tissue biopsy molecu-
lar analysis, liquid biopsy solutions are expected to generate a collective picture of 
cancer heterogenous clones enabling a comprehensive therapeutic approach which 
may be key to avoid clonal residual disease or recurrence [60].
A recent study evaluated the post-progression ctDNA (Guardant360 assay) with 
matched multiple lesion biopsies to assess heterogeneity during acquired resistance 
[61]. This study reveals distinct mutational profiles across metastatic lesions of 
gastrointestinal origin. The majority of private alterations across lesions could be 
detected by cfDNA. In another study, combined analysis of solid (192 genes) and 
liquid biopsies (27 genes) (OncoSTRAT&GO™, OncoDNA, Gosselies, Belgium), 
only found 40% of variants to be shared between the solid and liquid biopsy, with 
51% of variants being exclusive to tissue and 9% to blood [62]. The liquid exclusive 
variants increased to 14% after a year from tissue sampling reflecting temporal 
heterogeneity [62]. The disparity in mutation calling may be a result of distinct 
shedding rates across tumour stage and types or sensitivity of the ctDNA assay. 
Although further studies are needed, such studies suggest that liquid biopsy can 
complement tissue molecular pathology to improve the detection of clinically 
actionable aberrations to overcome spatial and temporal heterogeneity especially in 
late-stage disease.
3.2 Liquid biopsy for cancer detection
Similar to CDx assays, current solutions for primary cancer diagnosis are either 
ancillary solutions or to be used when the routine screening/diagnostic test is not 
an option. Thus, liquid biopsy approaches are currently another tool that assist 
and improve the overall performance of cancer detection. Approved liquid biopsy 
solutions for bladder cancer screening and colorectal cancer screening are avail-
able (Table 1) to support current screening methods. Evidently, when standard of 
care investigations are not available, liquid biopsy can provide means of detection. 
For instance, Epi proColon® (Epigenomics) is available only to patients who are 
unwilling or unable to be screened by recommended methods. This can potentially 
improve screening uptake with current colorectal cancer screening uptake reported 
between 53 and 61% [63–65]. The more acceptable, repeatable advantages of liquid 
biopsy enable multi-line testing or triage testing to select patients for further inves-
tigation, similar to the faecal immunochemical testing (FIT) to the colonoscopy 
procedure. Cologuard (ExactSciences) offers an approved stool molecular test for 
the detection of colorectal cancer with a reported increased sensitivity for detecting 
any stage CRC (92%) and 42% sensitivity for advanced precancerous lesions [12]. 
Specific cases presenting positive Cologuard test and negative follow-up colonos-
copy raised concerns for lack of recommendations for patient management in these 
scenarios [66].
A first-line or triage test should be cost-effective, especially for screening pur-
poses, to achieve a net cost–benefit. A recent health technology assessment evalu-
ates EGFR T790M resistance mutation testing in patients with advanced NSCLC 
can lead to fewer tissue biopsies although a follow-up confirmatory tissue biopsy is 
required when liquid biopsy tests negative [67]. EGFR T790M mutation detection 
from urine has also been shown to be feasible for NSCLC patients to reduce biopsy 
procedures and mitigate biopsy related complications [68].
In a similar approach, the ExoDx Prostate test (ExosomeDx, a Bio-Techne 
brand), can be used to assess cancer risk in patients with elevated prostate specific 
antigen (PSA) to assist the decision to proceed or defer a prostate biopsy. ExoDx 
is the first exosome-based (RNA biomarkers) liquid biopsy solution to receive a 
Breakthrough Device Designation by the U.S. FDA [69]. Prostate cancer screening 
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by PSA has highlighted the risks of over diagnosis and over treatment accompanied 
by a lack of tangible benefit [70, 71]. This created a need to better inform clini-
cal decisions to follow-up with invasive diagnostic procedures and treatment and 
accentuates the need for sensitive tests that are also highly specific. Specific clinical 
applications require performance parameters that balance risk of non-detection 
with overtreatment depending on the backbone standard of care tests.
3.3 Liquid biopsy for prognosis and therapy intervention
CellSearch® (Menarini Silicon Biosystems), a CTC detection system, was the 
first liquid biopsy approach to be approved by FDA in 2004. The CellSearch tech-
nology immunomagnetically captures CTCs from whole blood, that express the 
Epithelial cell adhesion molecule (EpCAM) and enumerates CTCs with the profile 
of CD45 negative and cytokeratin 8, 18, and/or 19 positive [72]. The CellSearch 
system provides prognostic information for patients with metastatic breast, 
prostate or colorectal cancer. A major limitation of this method is the reliance on 
the EpCAM marker. CTCs have been described to be heterogeneous and not all 
CTCs express EpCAM. Such methods are restrictive to the epithelial phenotype 
and have intrinsic selection bias [73]. Label-free CTC enrichment solutions, such 
as Parsortix® (ANGLE) and ClearCell® FX1 system (Biolidics) are European CE 
marked as in vitro diagnostic device (CE-IVD) solutions for CTC enrichment but 
require downstream analysis to derive clinically relevant information. Moreover, 
isolated CTC remain viable and can potentially be cultured and studied further 
although finding optimal conditions for culturing CTC subtypes is challeng-
ing [74]. CTC enrichment by size discrimination shows a reduced recovery rate 
(~60%) for smaller sized cell lines (SKBR3) [75] presenting with a selective 
enrichment and failing to detect a subset of cells similarly to immunoisolation 
methods. CTC enrichment by depletion of leukocytes also results in reduced 
recovery [76]. Current advances in flow cytometry resolution and imaging may 
enable the suppression of pre-enrichment to enable a quick and efficient detection 
of CTC [77–79]. These approaches have a definite role in therapeutic monitoring, 
identifying treatment response and early resistance and are ready for clinical 
studies [80, 81].
ctDNA abundance, mutation count and a KEAP1, KRAS, MET signature predict 
overall survival in advanced NSCLC patients (N = 949). Interestingly, patients with 
at least one ctDNA clearance during the course of treatment had a significantly 
better progression-free survival and overall survival than patients with consistent 
ctDNA levels throughout treatment [82]. The prognosis and predictive potential 
of ctDNA is yet to be translated into practical clinical assays. While the potential 
role of EV in cancer prognosis has been shown [83], further studies are required to 
define EV isolation and prognostic correlations in larger patient cohorts.
4. Current outlook for early cancer detection
5-year survival rates for patients diagnosed with stage I and stage IV cancer respec-
tively are 98% and 26% for breast cancer, 92% to 10% for colorectal cancer and 57% 
to 3% for lung cancer [84]. Earlier diagnosis would greatly improve cancer surviv-
ability but is currently a great challenge. Detecting cancer early is a cornerstone of the 
UK’s NHS Long term plan. There have been numerous efforts to achieve early cancer 
screening, through public awareness (Be Clear on Cancer and Detect Cancer Early 
campaigns), introducing new screening tests (Bowel screening) and targeted lung 
health checks (following the NELSON trial) and many more.
Histopathology and Liquid Biopsy
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Complex approaches, by GRAIL [85], Thrive’s CancerSEEK [86], 
FoundationMedicine, Base Genomics, Freenome aim to expand the potential 
of early diagnosis from blood. Grail’s Galleri, Thrive’s CancerSEEK and Natera’s 
Signatera have achieved FDA Breakthrough device status while in the trial 
stage. Early diagnosis remains a challenge with sensitivity being a critical factor. 
Achieving early diagnosis in the blood using ctDNA is more complex, mainly 
because there is a huge amount of “normal” DNA circulating in the blood. The 
smaller the cancer the smaller and less detectible the cancer signature is in the 
blood. As any cancer grows, it sheds more DNA, more cellular debris and more 
cancer cells into the bloodstream which eventually leads to the cancer spreading 
to distant organs. Although the ctDNA shedding rate can vary among patients, a 
mathematical model can predict tumour size by assessing haploid genome equiva-
lents per plasma volume (correlation: R2 = 0.32; P = 2.6x10–16) [87]. The smaller the 
tumour, the higher the probability of a false negative result for a particular action-
able mutation.
Till date there is no FDA-approved solution for early cancer detection from 
blood with targeted panel solutions available as ancillary diagnostics from stools for 
colorectal cancer (ColoGuard & Epi ProColon) and from urine for bladder cancer 
(Xpert Bladder Cancer detection & Uromonitor). Interestingly, a blood test detect-
ing Septin 9 (SEPT9) methylation to aid the detection of hepatocellular carcinoma 
(HCC) in patients with cirrhosis, has been CE-IVD marked (HCCBloodTest by 
Epigenomics) [9].
Following are some illustrative examples of ongoing clinical studies investigat-
ing the application of liquid biopsy for multi-cancer detection.
4.1 CancerSEEK, PapSEEK, UroSEEK
A series of liquid biopsy tests for early diagnosis have been developed at the 
Johns Hopkins University: CancerSEEK, PapSEEK and UroSEEK.
CancerSEEK measures 8 protein biomarkers by immunoassays and mutations 
on 16 genes by PCR and sequencing in blood samples to detect and localise the 
cancer. A study of eight cancer types (colorectal, ovary, pancreas, breast, upper 
gastrointestinal tract, lung and liver) resulted in a median sensitivity of 70%, rang-
ing from 33% in breast and 98% in ovarian cancer. Across stages of the disease the 
test was 43%, 73% and 78% sensitive respectively [86]. In a following prospective, 
interventional study (DETECT-A) CancerSEEK was coupled with positron emis-
sion tomography– computed tomography (PET-CT) for cancer detection. During 
this trial, the blood test sensitivity for all cancer types was 27.1% and specificity of 
98.9%. Of note, 108 participants out of 10,006 in this study had a positive blood 
test without cancer, most of who (101) were followed up by PET-CT and 38 also had 
a subsequent procedure to rule out cancer [34]. This highlights the importance of 
the high specificity levels required for potential screening tests and clearly defined 
second-line testing with a good consideration of the risk of overtreatment.
PapSEEK was developed for Pap brush samples or Tao brush samples and 
detects aneuploidy and somatic mutations on 18 genes by multiplex-PCR (AKT1, 
APC, BRAF, CDKN2A, CTNNB1, EGFR, FBXW7, FGFR2, KRAS, MAPK1, NRAS, 
PIK3CA, PIK3R1, POLE, PPP2R1A, PTEN, RNF43, and TP53). 81% endometrial 
cancer and 29% ovarian cancer were detected by PapSEEK on Pap brush samples 
which increased to 93% and 45% respectively when intrauterine samples were col-
lected using a Tao brush. False positive rate was 1.4% for Pap brush samples which 
improved to >99% specificity when using the Tao brush [88].
UroSEEK detects mutations within 11 genes (FGFR3, TP53, CDKN2A, ERBB2, 
HRAS, KRAS, PIK3CA, MET, VHL, MLL, TERT promoter) as well as aneuploidy. In 
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an early detection cohort UroSEEK was 83% sensitive and 93% specific while in the 
surveillance cohort sensitivity was 71% and specificity 80% which was a significant 
improvement compared to cytology alone [89].
4.2 Galleri
Recently, the UK’s National Health Service (NHS) has taken bold steps and 
will be partnering with GRAIL to confirm Galleri’s clinical and economic perfor-
mance in the NHS system [90]. The study will investigate the effectiveness of the 
Galleri test on 140,000 asymptomatic, healthy patients and 25,000 participants 
showing signs and symptoms of cancer. The Galleri test is a genome-wide test 
interrogating methylation patterns in plasma samples, optimised during the 
The Circulating Cell-free Genome Atlas Study (CCGA). Methylation patterns, 
measured by whole genome-bisulfite sequencing, were found to perform bet-
ter than whole genome and targeted (507genes) sequencing for the detection 
of cancer [85]. A further study to evaluate the performance of the optimised 
method, included 6,689 participants with more than 50 cancer types which were 
approximately equally distributed across stage of the disease (I- IV). The test 
achieved 99.3% specificity and 55.2% sensitivity across all cancers in the valida-
tion sets. Sensitivity improved when detecting more advanced cancer, reporting a 
detection of 39% of Stage I cancer, 69% of Stage II cancer and 83–92% sensitivity 
in Stage III & IV cancer. Cancer detection performance varied across different 
cancer types [85].
Such clinical studies represent landmark studies that paving the way for  
clinical service to initiate the introduction of liquid biopsy technologies for cancer 
screening.
5. Potential for EVs and integrative solutions
Tumour derived extracellular vesicles (EV) show great potential for liquid 
biopsy. EVs carry protein, DNA, RNA and small-RNA cargo shielding it from 
degradation [33, 91]. The cargoes carried by EVs represents a molecular fingerprint 
of the cell of origin [30]. A study comparing cfDNA and EV DNA in pleural effu-
sion for EGFR testing by qPCR, shows an improved detection rate when using EV 
DNA (72.2% vs. 61.1%) [28]. Moreover, research has described that 90% of prostate 
cancer ctDNA is found in large EVs [92]. EVs are released in abundant quantities 
presenting an intriguing solution for increase detection sensitivity [30]. TearExo® 
is a potential solution detecting EV diagnostic and prognostic markers from tears 
for diagnosis of breast cancer [27].
Despite these advantages, implementation of EVs into clinical cancer diagnostics 
is hampered by challenges and lack of standardisation in the isolation methods 
and analytical sensitivity [93]. With improved and standardised technologies and 
focused efforts, tumour EVs can potentially be used to selectively pick out tumour-
derived DNA from a background of normal DNA enhancing ctDNA technology 
sensitivity but also enable analysis of DNA, RNA and protein from the same 
sample, potentially for yet earlier detection.
Several challenges remain to be elucidated. EV populations are diverse and the 
functions and contents of EVs across their size distribution is not well known. The 
shedding rates across different tumour types or disease states are cannot be assessed 
without a standardised and accurate method for sizing and specific size isola-
tion. Several concerted efforts are leading the way to technical standardisation to 
robustly understand the role of EVs [93, 94].
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Solutions that integrate multi-modal testing are budding, such as Epic Sciences’ 
Comprehensive cancer profiling that performs CTC, ctDNA and immune-cell 
analysis from a single blood draw relying characterising protein, morphology and 
genomics. CancerSEEK integrates protein markers with ctDNA analysis. Such 
approaches may be key to unlock the full potential of liquid biopsies but present 
technical, workflow and interpretation challenges [95].
6. Conclusion
Liquid biopsy is currently a clinically useful tool for assisting companion diag-
nostics, cancer screening programmes and surveillance. There is an evident preva-
lence of ctDNA solutions which are already available for the companion diagnostic 
space and are expected to be accessing the earlier diagnostic space soon following 
clear delineation of the clinical value and applications. CTC solutions, the first 
approved liquid biopsy tool for clinical use, have a role in defining cancer prognosis 
and therapeutic monitoring for timely and effective therapeutic decisions. The 
clinical value and approach remain to be defined by further clinical studies and 
translation into practical, clinically applicable solutions.
The full potential of EVs is being uncovered with concerted efforts to establish 
rigour and standardisation driving reproducible research. Apart from the role of 
EVs for therapeutic applications, EVs show great potential for early diagnosis of 
cancer, therapeutic monitoring and post-therapeutic surveillance. Versatile and 
open technologies could facilitate integrated solutions to maximise the potential of 
liquid biopsy. Nonetheless, translation to the clinical setting will require practical 
solutions with clearly defined clinical applications.
Promising data is emerging across potential applications for liquid biopsy with 
multi-cancer early detection solutions expected in the near future.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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